8-K: USANA Health Sciences Amends Credit Agreement

USANA Health Sciences, Inc. has entered into a First Amendment to its Third Amended and Restated Credit Agreement, adjusting financial covenants and asset disposition limits.

Summary

• USANA Health Sciences, Inc. has amended its Third Amended and Restated Credit Agreement, dated June 27, 2025.
• The amendment, effective September 30, 2026, modifies financial covenants and operational flexibility.
• Key changes include adjustments to the minimum Consolidated EBITDA requirement and the general asset sale basket.
• A specific provision allows for the sale of real property in Sydney, Australia.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, primarily focused on operational adjustments to a credit agreement rather than core business performance.

Positives

• Increased flexibility in asset sales, with the general basket for property disposition increasing from $500,000 to $2,500,000.
• Specific allowance for the sale of real property in Sydney, Australia, providing potential liquidity.
• The minimum Consolidated EBITDA covenant has a conditional reduction to $70,000,000 if aggregate Revolving Exposure is $50,000,000 or less, offering a potential cushion.

Negatives

• The primary minimum Consolidated EBITDA covenant remains substantial at $100,000,000, which could be a constraint if performance falters.
• Sale and leaseback transactions remain generally prohibited, limiting certain strategic financial maneuvers.

Risks

• The company must maintain a minimum Consolidated EBITDA of $100,000,000, which could pose a risk if financial performance declines.
• The prohibition on most sale and leaseback transactions limits certain financing and operational strategies.

Future Outlook

The amendment adjusts covenants and operational flexibility within the existing credit facility, with no explicit forward-looking financial guidance provided in this document.

Management Comments

• The company and its subsidiaries reaffirmed all obligations under the Loan Documents.
• Loan parties confirmed the truthfulness and correctness of their representations and warranties.
• No default or event of default exists under the Loan Documents.

Industry Context

StockSavvy.ai notes that amendments to credit agreements are common for companies seeking to adjust financial covenants or operational terms in response to evolving business needs or market conditions. This particular amendment appears to grant slightly more flexibility in asset disposals while maintaining a significant EBITDA floor.

Stakeholder Impact

• Shareholders: The amendment provides slightly more operational flexibility regarding asset sales and a potential cushion on the EBITDA covenant, which could be viewed positively. However, the core financial obligations remain significant.
• Lenders: The amendment requires lender agreement and ensures reaffirmed obligations and liens, maintaining their security and oversight.
• Creditors: The continued adherence to financial covenants and the overall credit facility structure provides ongoing assurance of the company's financial commitments.

Next Steps

• USANA Health Sciences, Inc. must now comply with the amended Consolidated EBITDA covenant starting from the fiscal quarter ending October 3, 2026.
• The company may proceed with the sale of real property in Sydney, Australia, as permitted by the new covenant.
• The company and its subsidiaries will continue to operate under the terms of the Credit Agreement as amended.

Key Dates

Keywords

Credit Agreement Amendment, Consolidated EBITDA, Asset Sale, Revolving Credit Facility, Financial Covenant, Sale and Leaseback, USANA Australia